Preclinical Toxicological Characterization of Porphyrin-Doped Conjugated Polymer Nanoparticles for Photodynamic Therapy
Pharmaceutics · 01.05.2025 · 17 (5) · 593
DOI: 10.3390/pharmaceutics17050593 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 01.05.2025. Verfasst von Matías Daniel Caverzan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Investigaciones en Tecnologías Energéticas y Materiales Avanzados (IITEMA), Universidad Nacional de Río Cuarto (UNRC) y Consejo Nacional…. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agencia Nacional de Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación, Consejo Nacional de Investigaciones Científicas y Técnicas, National University of Río Cuarto.
Abstract (Originalsprache)
Background
Photodynamic therapy (PDT) utilizing nano-based photosensitizers (PSs) offers promising cancer treatment potential but requires rigorous safety evaluation. Conjugated polymer nanoparticles (CPNs) doped with porphyrins, such as platinum porphyrin–doped poly(9,9-dioctylfluorene-alt-benzothiadiazole) (F8BT), exhibit enhanced photodynamic efficiency but lack comprehensive preclinical toxicity data. This study aimed to evaluate the biocompatibility, biodistribution, and acute/subacute toxicity of these CPNs to establish their safety profile for clinical translation.
Methods
CPNs were synthesized via nanoprecipitation using amphiphilic stabilizers (PSMA or PS-PEG-COOH) and characterized for colloidal stability in parenteral solutions. Hemolysis assays were used to assess blood compatibility. Single-dose (0.3 and 1 mg/kg, intravenous) and repeated-dose (0.1–1 mg/kg, intraperitoneal, every 48 h for 28 days) toxicity studies were conducted in BALB/c mice. Hematological, biochemical, histopathological, and biodistribution analyses (via ICP-MS) were performed to evaluate systemic and organ-specific effects.
Results
CPNs demonstrated excellent colloidal stability in 5% dextrose, with minimal aggregation. No hemolytic activity was observed at concentrations up to 50 mg/L. Single and repeated administrations revealed no significant changes in body/organ weights, hematological parameters (except transient fibrinogen elevation), or liver/kidney function markers (ALT, AST, BUN, Cr). Histopathology showed preserved tissue architecture in major organs, with mild hepatocyte vacuolation at 30 days. Biodistribution indicated hepatic/splenic accumulation and rapid blood clearance, suggesting hepatobiliary elimination.
Conclusions
Platinum porphyrin–doped F8BT CPNs exhibited minimal acute and subacute toxicity, favorable biocompatibility, and no systemic adverse effects in murine models. These findings support their potential as safe PS candidates for PDT. However, chronic toxicity studies are warranted to address long-term organ accumulation and metabolic impacts. This preclinical evaluation provides a critical foundation for advancing CPNs toward clinical applications in oncology.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Instituto de Investigaciones en Tecnologías Energéticas y Materiales Avanzados (IITEMA), Universidad Nacional de Río Cuarto (UNRC) y Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Río Cuarto X5800…
- Instituto de Biotecnología Ambiental y Salud (INBIAS), Universidad Nacional de Río Cuarto (UNRC) y Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Rio Cuarto X5800BIA, Argentina.
- Institute of Endotypes in Oncology, Metabolism and Immunology "Gaetano Salvatore", National Research Council, 80131 Naples, Italy.
ORCID-Profile: Matías Daniel Caverzan, Luis Exequiel Ibarra
Förderung
- Agencia Nacional de Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación
- Consejo Nacional de Investigaciones Científicas y Técnicas
- National University of Río Cuarto
- SECyT UNRC
- ANPCyT
- CONICET
- Join Bilateral agreement CNR/CONICET
Zitieren
APA
Caverzan, M. D., Morales Vasconsuelo, A. B., Cerchia, L., Palacios, R. E., Chesta, C. A., & Ibarra, L. E. (2025). Preclinical Toxicological Characterization of Porphyrin-Doped Conjugated Polymer Nanoparticles for Photodynamic Therapy. Pharmaceutics, 17(5), 593. https://doi.org/10.3390/pharmaceutics17050593
Vancouver
Caverzan MD, Morales Vasconsuelo AB, Cerchia L, Palacios RE, Chesta CA, Ibarra LE. Preclinical Toxicological Characterization of Porphyrin-Doped Conjugated Polymer Nanoparticles for Photodynamic Therapy. Pharmaceutics. 2025;17(5):593. doi:10.3390/pharmaceutics17050593
BibTeX
@article{Caverzan2025,
author = {Caverzan, Matías Daniel and Morales Vasconsuelo, Ana Belén and Cerchia, Laura and Palacios, Rodrigo Emiliano and Chesta, Carlos Alberto and Ibarra, Luis Exequiel},
title = {Preclinical Toxicological Characterization of Porphyrin-Doped Conjugated Polymer Nanoparticles for Photodynamic Therapy},
journal = {Pharmaceutics},
year = {2025},
volume = {17},
number = {5},
pages = {593},
doi = {10.3390/pharmaceutics17050593}
}
EUVIMED